Pilot corpus: NIH-funded biomedical datasets. Any DOI can be scored on demand — network effects sharpen as coverage grows.

Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms

Molecular Metabolism(2020)10.1016/j.molmet.2020.101139Source: DataRank Database

Targeting the GIPR for obesity: To agonize or antagonize? Potential mechanisms is a research paper published in Molecular Metabolism (2020). On theSindex it has a DataRank of 0. It has been cited 126 times.

N/A

0DataRank · unranked

Scored on demand from live citation data

Open Access126 citations

Download PDF

Cite:

Linked data & code

doi

DataRank reads this dataset's downstream impact straight off the citation graph — no black box, no proprietary weighting. How is this computed?

›Methodology & internals

datarank_citation_only_1hop_v6· scope data_onlyMethodology

Pipeline:MetadataData-paper checkEnrichmentCitation networkScoring

Enrichment:Funding (6 grants)Impact (FWCI 7.45)OA: goldTopics (62)IDs (PubMed, PMC, OpenAlex)Annotations (1)SDGs (2)

FAIR Checklist

Context only (not used in score)

Findable (1/2)

Has DOI

Accessible (1/2)

Open Access

Interoperable (0/2)

Reusable (0/3)

FAIR checklist signals are shown for context only and do not affect DataRank scoring.

Run a calibrated FAIR evaluation for this paper →

We only score data papers we can read in full — never from an abstract alone.

Authors (1)

Jonathan E. Campbell ORCID

Live enrichment

PubMed:33290902 PMC:PMC8085569 OpenAlex:https://openalex.org/W3111709040

NIDDK NIH HHS

Grant: R01 DK123075

NIDDK NIH HHS

Grant: R01 DK125353

National Institutes of Health

Grant: 7R01NR012307-02

Patterned Experience for Preterm Infants

National Institutes of Health

Grant: 5R01DK125353-03

Novel metabolic actions of GIP

American Diabetes Association

National Institutes of Health

FWCI

7.45

Citation Percentile

1.0%

Citation Trend

2020

2021

2022

2023

2024

2025

2026

goldLicense: cc-by-nc-nd

journalhttps://www.sciencedirect.com/science/article/pii/S2212877820302131/pdf

publisherhttps://www.sciencedirect.com/science/article/pii/S2212877820302131/pdf

publisherhttps://api.elsevier.com/content/article/PII:S2212877820302131?httpAccept=text/xml

publisherhttps://api.elsevier.com/content/article/PII:S2212877820302131?httpAccept=text/plain

journalhttps://doi.org/10.1016/j.molmet.2020.101139

Fields of Study

Diabetes Treatment and ManagementNeuropeptides and Animal PhysiologyRegulation of Appetite and Obesity0301 basic medicine0303 health sciences03 medical and health sciencesAdipose TissueAnimalsBody WeightDiabetes Mellitus, Type 2Gastric Inhibitory PolypeptideGlucagon-Like Peptide 1Glucagon-Like Peptide-1 ReceptorHumansIncretinsMiceMice, KnockoutObesityWeight GainGlucagon-Like Peptide-1 Receptor Agonists

MeSH Terms

Glucagon-Like Peptide-1 ReceptorGlucagon-Like Peptide-1 Receptor AgonistsAdipose TissueAnimalsBody WeightDiabetes Mellitus, Type 2Gastric Inhibitory PolypeptideHumansObesityWeight GainMice, KnockoutMiceGlucagon-Like Peptide 1Incretins

Keywords

IncretinInternal medicineEndocrinologyAntagonismObesityHormoneGlucagon-like peptide-1BiologyMedicineType 2 diabetesDiabetes mellitusReceptorIncretinsGlucose-dependent Insulinotropic Polypeptide (Gip)Mice, KnockoutBody WeightReviewGastric Inhibitory PolypeptideWeight GainRC31-1245Glucagon-Like Peptide-1 ReceptorMiceAdipose TissueDiabetes Mellitus, Type 2Glucagon-Like Peptide-1 Receptor AgonistsGlucagon-Like Peptide 1AnimalsHumans

Sustainable Development Goals

SDG 2: 2. Zero hungerSDG 0: Good health and well-being